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The study was aimed at evaluating apoptotic potential of Br-oxph (4-bromo-
N,N-diethyl-5,5-dimethyl-2,5-dihydro-1,2-oxaphosphol-2-amine  2-oxide)  in  vitro.  The 
dose response effect of Br-oxph (dose range 1-3 mg/ml, for 48 h) on SK-MES-1 cells 
viability was determined by means of WST-1 cell proliferation assay. The half maximal 
inhibitory concentration (ІС50) value was determined – 1.8 mg/ml. The ability of the 
compound  tested  to  induce  apoptosis  was  tested  by  ELISA  to  detect  cellular  DNA 
fragmentation. We provided a quantitative assessment of the apoptotic potential of Br-
oxph  in  human  lung  carcinoma  cells  at  concentrations  corresponding  to  ІС50  and 
2хІС50  for  3  hours.  Treatment  with  2хІС50  significantly  increased  the  amount  of 
cytoplasmic DNA-fragments. Results obtained from the present study confirm that Br-
oxph target the cancerous cells towards apoptosis. 
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INTRODUCTION 
4-bromo-N,N-diethyl-5,5-dimethyl-2,5-dihydro-1,2-oxaphosphol-2-amine2-oxide  (Br-
oxph)  belongs  to  the  family  of  heterocyclic  compounds,  containing  phosphorus  and  oxygen 
atoms in the ring – oxaphospholes (Figure 1). Oxaphospholes possess biological activity, which 
is  not  well  studied.  Br-oxph  is  a  structural  analogue  to  furanoses.  Furanoses  are  abundant 
constituents of natural products, including nucleic acids. Nucleoside-analogue derivatives have 
received wide attention as antiviral drugs (TAM et al., 2000; KAMIYA, 2003; PESCOVITZ, 2008; 
OKANO, 2009). Another compound with structural similarity to Br-oxph is cyclophosphamide. 
Cyclophosphamide belongs to a class of drugs known as alkylating agents, which have been used 
to treat some types of cancer (KANNO et al., 2009; SHARABI and HARAN-GHERA, 2011). 2                                                                                                                    GENETIKA, Vol. 46, No.1 ,1-10, 2014 
 
Figure 1. Molecular models are optimized with Firefly QC package (GRANOVSKY, Firefly version 7.1.G), 
which is partially based on the GAMESS (US) (SCHMIDT et al., 1993) source code. Provided to 
us by A. Patleeva. 
 
Organophosphorus compounds are widely used as pesticides (RICHARDS et al., 2000; 
CASIDA and DURKIN, 2013). In previous study in vivo we established cytotoxic and genotoxic 
effects of Br-oxph at low doses in plant and animal test-systems (KALCHEVA et al., 2009 a). 
Clastogenic  effect  of  Br-oxph  at  very  low  dose  (2.82x10
-9  µg/kg)  was  confirmed  at  the 
ultrastructural level using atomic force microscopy (KOLEVA et al., 2013). These results revealed 
that possible application of Br-oxph as agrochemical could affect negatively environmental and 
human health.  
Another sign of cytotoxicity of Br-oxph was apoptotic-like effect. Using conventional 
light microscopy we observed nuclear fragmentation and condensation in mice bone marrow 
cells after treatment with Br-oxph (KALCHEVA et al., 2009 a; KALCHEVA et al., 2009 b). The 
analysis  via  AFM  (KOLEVA  et  al.,  2013)  also  confirmed  morphology  changes  described  in 
apoptotic nuclei by others (KAM and FERCH, 2000; GORNEVA et al., 2005; PELZEL et al., 2010). 
Apoptosis is a key point in therapeutical effects of anticancerous drugs (BACSÓ et al., 2000). 
Most  chemotherapy  drugs  are  genotoxic  (TURINETTO  et  al.,  2009)  and  effectiveness  of 
chemotherapy depends on inhibition of cell proliferation and/or triggering of apoptosis in tumor 
cells (JESSEN et al., 2005; SHENOY et al., 2007; RASTOGI et al., 2009).  
Clastogenic and apoptotic effects of Br-oxph in vivo raise the hypothesis of another 
possible application of compound studied – growth inhibition of tumor cells. The objective of 
present study was to determine the apoptotic potential of Br-oxph in human cancerous cells lines. 
 
MATERIALS AND METHODS 
Chemicals and reagents 
MEM  growth  media  and  fetal  calf  serum  were  purchased  from  РАА  (Аustria). 
Premixed WST-1 Cell Proliferation Reagent and Cellular DNA Fragmentation ELISA kit were 
purchased from Roche Applied Science. V. KOLEVA: INDUCTION OF APOPTOSIS BY BR-OXPH                                                                          3 
Br-oxph was synthesized in the Laboratory of Organic Chemistry of the University of 
Shumen (Bulgaria) (ANGELOV and ENCHEV, 1987). Stock solutions of Br-oxph (1 mg/ml, 1.5 
mg/ml,  2  mg/ml,  2.2  mg/ml,  2.4  mg/ml,  2.6  mg/ml,  2.8  mg/ml  and  3  mg/ml)  were  freshly 
prepared in MEM. 
 
Cell lines and culture conditions 
The SK-MES-1 was obtained from National Bank for industrial Microorganisms and 
Cell  Cultures  (Bulgaria).  The  cells  were  maintained  as  adherent  in  controlled  environment: 
MEM medium, supplemented by 10% heat-inactivated fetal calf serum, in incubator at 37ºC, 5% 
CO2 and humidified atmosphere. In order to keep cells in log phase, the cultures were refed with 
fresh medium two or three times/week. 
 
In vitro cytotoxicity assay (dose-response relationship) 
Cell  viability  was  assessed  using  Premixed  WST-1  Cell  Proliferation  Reagent.  The 
assay principle is based upon the reduction of the tetrazolium salt WST-1 to formazan in the 
mitochondria of living cells. Exponentially growing cells were seeded in 96-well flat-bottomed 
microplates (100 µL/well) at a density of 2х10
4 cells per ml. Time of treatment was 48 hours. 
Four hours before the end of incubation time, cell proliferating reagent WST-1 (10 µl/ well) was 
added  to  the  culture  media.  Microplates  were  further  incubated  for  4  hours  at  37
◦C.  The 
absorbance of formazan product was quantitated at 450 nm using an ELISA reader. The cell 
survival fractions were calculated as a percentage of the untreated control (untreated control = 
100%). Dose response curves were created by plotting the percent of viable cells versus the test 
concentrations. Concentration of Br-oxph showing 50% reduction in cell viability (half maximal 
inhibitory concentration value, IC50) was then calculated. 
 
DNA fragmentation analysis 
The  ability  of  Br-oxph  to  induce  apoptosis  was  studied  using  Cellular  DNA 
Fragmentation ELISA kit as per supplier’s instructions. Briefly, the cell number was adjusted to 
3х10
5  cells/ml  in  the  culture  medium  and  BrdU  labeling  solution  was  added  to  a  final 
concentration of 10 µM. After BrdU labelling for 4 h cells were treated with ІС50 (1.8 mg/ml) 
and 2хІС50 (3.6 mg/ml) Br-oxph for 3 h. Cells were lysed and centrifuged at 250 g for 10 
minutes. Each well of anti-DNA antibody coated microtiter plate were added with 100 µl of the 
supernatant. Further analysis was provided by ELISA, using the instructions recommended by 
the manufacturer. 
 
Data processing and statistics 
The cytotoxicity assays were carried out in 9 replicate wells. Tthe apoptosis induction 
evaluation was conducted in 6 replicate wells. The values for each concentration tested represent 
the average (mean ± SD). Student’s t-test was performed with P≤0.05 taken as significance level. 
 
RESULTS AND DISCUSSION 
Experiments aimed to determine the dose response effect of Br-oxph (dose range 1-3 
mg/ml, for 48 h) on SK-MES-1 cells proliferation/viability were carried out by means of WST-1 
cell proliferation assay. The results revealed concentration-dependent and statistically significant 
(Р≤0.001)  inhibition  effect  of  Br-oxph  at  concentrations  tested  (Figure  2).  As  can  be  seen, 4                                                                                                                    GENETIKA, Vol. 46, No.1 ,1-10, 2014 
treatment with 1 mg/ml Br-oxph showed about 24% reduction in cell viability. After addition of 
1.5 mg/ml Br-oxph viability was reduced by 40%. The inhibitory effect of the compound tested 
increased at dose range 2-2.4 mg/ml (reduction in cell viability about 57%). The percent of 
viable cells decreased at higher concentrations tested: after treatment with 3 mg/ml Br-oxph 
only 26% of cells survived. 
 
 
 
 
 
Figure 2. Effect of Br-oxph on cell proliferation/cell viability of lung carcinoma cell line (SK-MES-1). *** 
Р≤0.001. 
 
 
From  the  curve  based  on  the  obtained  values  plotted  as  percentage  of  viable  cells 
against Br-oxph test concentrations the ІС50 were obtained – 1.8 mg/ml. 
As a next step, we checked the ability of Br-oxph to induce apoptosis, a process that 
removes highly damaged cells. A hallmark of apoptosis is fragmentation of the DNA and DNA-
histone complex are released to the cytoplasm (AU and WIENTJES, 1999; BACSÓ et al., 2000). We 
provided a  quantitative  assessment  of  the  apoptotic  potential  of  Br-oxph  at  concentrations 
corresponding to ІС50 and 2хІС50. Consistent with other studies (BACSÓ et al., 2000; KRÜGER 
et al., 2009; MUTEE et al., 2012) the duration of the treatment was 3 h. 
The  effect  of  treatment  with  Br-oxph  (1.8  mg/ml  and  3.6  mg/ml)  for  3  hours  on 
internucleosomal  DNA  fragmentation  in  lung  carcinoma  cells  is  shown  in  Figure  3.  The 
apoptotic  effect  of  compound  tested  is  dose  dependent.  After  treatment  with  Br-oxph  at 
concentration 1.8 mg/ml (ІС50) we observed only slight elevation of the DNA-fragments in 
cytoplasm  –  by  11%  in  comparison  with  the  control.  Treatment  with  2хІС50  significantly 
increased the amount of DNA-fragments – by 33% as compared to the control. This finding is in 
accordance with our previous results revealing clastogenic activity of compound tested in mice 
bone marrow cells 3 h after the treatment (KALCHEVA et al., 2009 a; KALCHEVA et al., 2009 b). V. KOLEVA: INDUCTION OF APOPTOSIS BY BR-OXPH                                                                          5 
 
Figure 3. Apoptosis induction by Br-oxph in lung carcinoma cell line SK-MES-1 as determined by ELISA 
for DNA Fragmentation. * Р≤0.05. 
 
 
The results of our studies revealed clastogenic effects of Br-oxph on cellular DNA. 
According to BOLDERSON et al. (2009) the potential ways to manipulate DNA damage response 
could impact enormously future medical science. The established antiproliferative and apoptotic 
activity of Br-oxph raises the possibility of using the compound tested in treatment of some 
human  cancers.  DNA  double-strand  breaks  (DSBs)  are  potentially  lethal  events  for  the  cell 
(HALAZONETIS et al., 2008; ROOS and KAINA, 2013). The answer of the cell is DNA repair and/or 
cell  cycle  blocking.  In  occasion  of failure  of the  repair  machinery  to  rejoin  the  breaks,  the 
programmed  cell  death  was  triggered  (LIM  et  al.,  2009;  SHI  and  OBERDOERFFER,  2012). 
Programmed cell death (apoptosis) is also a key mechanism by which anticancer therapies exert 
their therapeutic effects (BACSΌ et al., 2000). The transcription factor р53 plays a key role in 
both types of cell answer (HOSAKO et al., 2007; OZAKI and NAKAGAWARA, 2011; REINHARDT and 
SCHUMACHER, 2012; XU et al., 2013). Taking into account apoptotic and clastogenic activity of 
Br-oxph, we can speculate that the compound tested induces apoptosis by mechanism involving 
р53 (Figure 4). Under normal conditions, p53 is expressed at an extremely low level, which is 
caused  by  proteasomal  degradation  mediated  largely  by  ligase  MDM2  (OZAKI  and 
NAKAGAWARA, 2011). ATM-kinase (Ataxia-Telangiectasia Mutated) is the predominant kinase 
responsible  for  the  activation  of  multiple  cell  cycle  checkpoints  following  DSB  induction 
(BOLDERSON et al., 2009). ATM phosphorylates Chk2 (checkpoint kinase-2) after the formation 6                                                                                                                    GENETIKA, Vol. 46, No.1 ,1-10, 2014 
of DSBs. In turn, Chk2 phosphorylate the transcription factor p53. This prevents its proteosomal 
degradation  and  p53  transcriptionally  regulates  pro-apoptotic  genes  such  Bax,  Puma,  Noxa 
(OZAKI and NAKAGAWARA, 2011; SONG et al., 2011; REINHARDT and SCHUMACHER, 2012). 
 
 
 
Figure 4. A possible mechanism of triggering apoptosis after treatment with Br-oxph. 
 
There is a clear need for new and effective drugs for different kind of malignancies 
(BURGER  and  FIEBIG,  2004;  ABU-SURRAH  and  KETTUNEN,  2006).  Drug  development  is 
complicated, time-consuming, and costly process. ZHOU and WONG (2006) described a recently 
emerged  promising solution  to  improve  the  quality  of  decisionmaking  in  drug  development. 
According to authors, cell-based assays could be used for the development of new drugs starting 
from  primary  screening  to  in  vitro  toxicology.  Using  such  a  strategy  in  present  study  we 
established  antiproliferative and  apoptotic  activity  of Br-oxph,  suggesting  possible  antitumor 
activity. 
One of the greatest problems is the selective killing of different type cancer cells. For 
this  reason  the  other  goal  of  our  study  was  to  examine  the  antiproliferative  and  apoptotic 
activity  of Br-oxph in  different cancerous cell line. We provided WST-1 Cell Proliferation 
Assay  using  Human  hepatoma  cell  line  SK-HEP-1.  The  preliminary  results  revealed  that 
inhibitory effect of Br-oxph on SK-HEP-1 cells was much stronger than those observed in SK-
MES-1 cell line: after treatment with 2 mg/ml survived cells were 7% in comparison with 
control (data not presented). These results suggest selective cytotoxic influence of Br-oxph on 
different type cancer cells. 
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CONCLUSION 
The data obtained in present study showed cytotoxic and apoptotic activity of Br-oxph 
(1.8 mg/ml and 3.6 mg/ml) for 3 hours on lung carcinoma cell line SK-MES-1. These results 
suggest necessity of further studies about possible application of Br-oxph as anticancerogenous 
compound. 
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SPREČAVANJE ŠIRENJA I INDUKCIJA APOPTOZE U LJUDSKIM ĆELIJAMA 
RAKA PLUĆA POMOĆU BR-OXPH 
 
Vanja KOLEVA
1,*, Asja DRAGOEVA
1, Marian DRAGNOV
2, Laura  MELENDEZ-
ALAFORT
3, Antonio ROSATO
3, Nikolaj UZUNOV
1, Dobromir ENHCEV
1 
 
1 Prirodno matematički fakultet, Univerzitet Šumen, Bugarska 
2 Medicinski Univerzitet u Plovdivu, Bugarska 
3 Institut Veneto Oncologico IRCCS, Padova, Italija 
 
Izvod 
Studija  je  imala  cilj  procenu  apoptotskog  potencijala  Br-  oxph  (4-bromo-N,N-diethyl-5,5-
dimethyl-2,5-dihydro-1,2-oxaphosphol-2-amine 2-oxide) in vitro. Efekat doznog odgovora  Br-
oxph (veličina doze 1-3 mg/ml, za 48 sati) na vitalnost SK-MES-1 ćelija je određen  pomoću 
VST -1 testa proliferacije ćelija.  Vrednost polu – maksimalne inhibitorne koncentracije (ІС50) 
određena je na 1.8 mg/ml. Sposobnost testiranog jedinjenja da indukuje apoptozu je ispitana 
pomoću ELISA testa sa ciljem da se  detektuje ćelijska DNK fragmentacija. Obezbedili smo 
kvantativnu procenu apoptotskog potencijala Br-oxph kod ćelija ljudskog karcinoma pluća u 
koncentracijama koje odgovaraju IC 50 i 2 x IC50 za 3 sata.   Lečenje pomoću 2 x IC 50 znatno 
je povećalo količinu citoplazmatskih fragmenata DNK. Rezultati dobijeni iz ove studije da Br-
oxph ciljno napadaju kancerogene ćelije u smeru apoptoze.  
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